Trauma BPE Prolonged Exposure Therapy for Injured Individuals Admitted to a Level I Trauma Center
Launched by BAYLOR RESEARCH INSTITUTE · Jan 17, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Trauma BPE Prolonged Exposure Therapy for Injured Individuals," is studying a brief treatment method aimed at preventing posttraumatic stress disorder (PTSD) and other related issues that can occur after a traumatic injury. The researchers want to find out if this therapy can help individuals who have been hurt and are being treated at certain trauma centers, specifically Baylor University Medical Center in Dallas, Baylor Scott & White Medical Center in Temple, or Froedtert Hospital in Wisconsin.
To participate in this trial, individuals must be between the ages of 18 and 65 and have been admitted to one of the listed trauma centers. However, some people won't be eligible; for example, those who are not fluent in English, have severe cognitive difficulties, are in police custody, or are dealing with serious mental health issues like acute suicidal thoughts or active psychosis. If you qualify and choose to participate, you can expect to receive a brief therapy designed to address the emotional challenges that can follow a traumatic injury. This trial is not yet recruiting participants, but it aims to provide valuable insights into how we can better support those recovering from traumatic events.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between the ages of 18 and 75 years old.
- • Admitted to Baylor University Medical Center at Dallas (BUMC), Baylor Scott \& White Medical Center at Temple (BSWMC), or Froedtert Hospital and the Medical College of Wisconsin (FH/MCW) Level 1 Trauma Center
- Exclusion Criteria:
- • Patients in police custody
- • Patients not fluent in English
- • Patients with severe cognitive impairment
- • Patients who are acutely suicidal
- • Patients with active psychosis
About Baylor Research Institute
Baylor Research Institute (BRI) is a leading clinical research organization affiliated with Baylor Scott & White Health, dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a focus on translational medicine, BRI conducts a wide range of clinical trials across various therapeutic areas, including cardiovascular, oncology, and neurology. The institute is committed to fostering collaborative partnerships with academic institutions, industry leaders, and healthcare professionals to enhance the development of novel therapies and interventions. Through rigorous scientific methodology and ethical standards, Baylor Research Institute strives to contribute significantly to the advancement of healthcare and to provide patients with access to cutting-edge treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Milwaukee, Wisconsin, United States
Temple, Texas, United States
Patients applied
Trial Officials
Ann Marie Warren, PhD
Principal Investigator
Baylor Scott & White Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported